Published on

Urology – Locally Advanced Prostate Cancer: Pathological T3–T4 Following Radical Prostatectomy

Definition, Pathological Staging, Surgical Margins, Postoperative PSA, Adjuvant and Salvage Radiotherapy, ADT, Prognosis, and Follow-Up

1. Definition and Clinical Overview

Pathologically locally advanced prostate cancer refers to prostate adenocarcinoma found on examination of the radical prostatectomy specimen to extend beyond the prostate gland or invade adjacent structures.

The original chapter focuses primarily on pT3–pT4 disease without regional lymph node or distant metastases (pN0M0).

Pathological staging is established by histological examination of the removed prostate, seminal vesicles, and, when sampled, regional lymph nodes.

Important Pathological Features

  • Extraprostatic extension.
  • Seminal vesicle invasion.
  • Invasion of adjacent anatomical structures.
  • Positive surgical margins.
  • Lymph node involvement.
  • Tumour Grade Group and volume.

These factors help predict the risk of persistent PSA, biochemical recurrence, metastatic progression, and prostate cancer-specific mortality.

Key Clinical Principle: Pathologically Advanced Prostate Cancer Requires Postoperative Risk Assessment Based On Tumour Extent, Grade Group, Margin Status, Nodal Status, And PSA Response To Determine The Need For Additional Treatment.


2. Pathological TNM Staging

pT3a – Extraprostatic Extension

Cancer extends beyond the prostate gland into surrounding tissues.

This category also includes microscopic invasion of the bladder neck under contemporary TNM classification.

pT3b – Seminal Vesicle Invasion

Cancer directly invades one or both seminal vesicles.

Seminal vesicle invasion is generally associated with a more adverse prognosis than extraprostatic extension alone.

pT4 – Invasion of Adjacent Structures

Tumour invades adjacent structures other than the seminal vesicles.

Examples include:

  • External urethral sphincter.
  • Rectum.
  • Levator muscles.
  • Pelvic wall.
  • Extensive invasion of adjacent bladder structures.

Important Staging Qualification

The historical source places bladder neck invasion under pT4.

Microscopic Bladder Neck Invasion Is Classified As pT3a In Contemporary Staging. It must not automatically be classified as pT4.

Nodal and Metastatic Status

  • pN0: No regional lymph node metastases identified.
  • pN1: Regional lymph node metastases.
  • M0: No distant metastatic disease.
  • M1: Distant metastases.

Pathological T stage and lymph node status are separate components of staging. A patient with pT3 disease may be pN0 or pN1.


3. Clinical Versus Pathological Staging

Clinical staging is based on pretreatment assessment, while pathological staging is determined from the surgical specimen.

Clinical Assessment May Include

  • Digital rectal examination.
  • Prostate MRI.
  • PSA.
  • Biopsy findings.
  • Other staging investigations.

Pathological Assessment Includes

  • Actual extent of tumour invasion.
  • Extraprostatic extension.
  • Seminal vesicle involvement.
  • Surgical margin status.
  • Lymph node histology.

Upstaging

A tumour initially considered clinically organ-confined is found to have extraprostatic extension or seminal vesicle invasion.

Downstaging

The pathological extent is less advanced than predicted clinically.

Historical Source Findings

  • Approximately 3% of patients were down-T-staged.
  • Approximately 35% were up-T-staged.

These figures represent a historical study rather than contemporary universal rates.

Clinical Pearl: Final Radical Prostatectomy Pathology Often Provides More Accurate Prognostic Information Than Preoperative Clinical Stage Alone.


4. Epidemiology

Historical Stage Migration

The widespread introduction of PSA testing led to more prostate cancers being detected at earlier stages.

The source reports a relatively stable rate of pathological extraprostatic extension of approximately:

25% since 2001 in the historical cohorts examined.

Screening Changes

The original chapter discusses changes to PSA screening recommendations in 2012–2013 and concern that reduced screening could increase the proportion of advanced presentations.

Contemporary Qualification

The relationship between screening practice and stage at diagnosis varies by population and healthcare system.

Historical rates should not be used as current incidence estimates.


5. Risk Factors for Advanced Pathological Disease

The risk of finding pT3–pT4 cancer increases with adverse preoperative characteristics.

Important Predictors

  • Elevated pretreatment PSA.
  • High Gleason score.
  • High ISUP Grade Group.
  • Advanced clinical T stage.
  • Extensive tumour involvement on biopsy.
  • Greater MRI-defined tumour extent.

Additional Historical Associations

The source mentions:

  • Obesity.
  • Poor health literacy.
  • Inadequate screening access.
  • Frequent multivitamin consumption.

These associations require cautious interpretation and do not establish direct causation.

Clinical Importance

High PSA, High Histological Grade, And Extensive Tumour Involvement Increase The Probability Of Advanced Disease On Final Prostatectomy Pathology.


6. Preoperative Risk Prediction

Partin Tables

Historically use:

  • PSA.
  • Clinical T stage.
  • Gleason score.

To estimate probabilities of:

  • Organ-confined disease.
  • Extraprostatic extension.
  • Seminal vesicle invasion.
  • Lymph node involvement.

D'Amico Risk Classification

Classifies prostate cancer into broad:

  • Low-risk.
  • Intermediate-risk.
  • High-risk.

Categories based on PSA, Gleason score, and clinical stage.

Contemporary Practice

Modern risk assessment may additionally incorporate:

  • ISUP Grade Group.
  • Multiparametric MRI.
  • Percentage of positive biopsy cores.
  • PSA density.
  • Validated nomograms.

Important Principle

Prediction Models Support Counseling But Cannot Replace Final Histopathological Examination.


7. Genetics and Molecular Markers

The historical chapter identifies several molecular changes associated with advanced prostate cancer.

Historical Associations

  • Abnormal p53 expression.
  • Reduced p16 expression.
  • Retinoblastoma pathway dysregulation.
  • Chromosome 9 abnormalities.

Historical Commercial Assays

The source mentions the introduction of:

  • Prolaris.
  • Oncotype DX Prostate.

These assays use tumour gene-expression information to help estimate biological aggressiveness.

Contemporary Context

Selected genomic classifiers, including Decipher, may offer additional prognostic information following prostatectomy.

Clinical Importance

Genomic assays may help refine risk estimates in selected patients, but they do not replace established clinicopathological features.


8. Pathophysiology of Extraprostatic Extension

Prostate cancer develops the ability to invade surrounding tissues through malignant changes in cell growth, adhesion, and tissue invasion.

Important Mechanisms

  • Disruption of normal tissue barriers.
  • Extracellular matrix degradation.
  • Perineural spread.
  • Lymphovascular invasion.
  • Infiltration of periprostatic tissues.

Anatomical Pattern

Peripheral-zone tumours commonly extend:

  • Posteriorly.
  • Posterolaterally.

These are important regions because of their proximity to the prostatic capsule and neurovascular structures.

Clinical Importance

Posterolateral Extraprostatic Extension Is Particularly Relevant To Surgical Margins And Nerve-Sparing Decisions.


9. Tumour Volume

The historical source describes an association between increasing tumour volume and pathological extension.

Historical Thresholds

Extraprostatic extension was more commonly observed with tumour volume greater than:

0.5 cm³.

Seminal vesicle invasion was more commonly observed with tumour volume greater than:

4 cm³.

Important Qualification

These are historical observational thresholds, not modern diagnostic cutoffs.

Multivariable Prognosis

The source notes that tumour volume may not independently predict progression after accounting for:

  • Grade.
  • Pathological stage.
  • Surgical margins.

Clinical Importance

Tumour Volume Contributes To Risk Assessment, But Grade, Stage, And Margin Status Often Provide Stronger Independent Prognostic Information.


10. Clinical History and Presentation

Patients undergoing prostatectomy may initially have clinically localized disease, with advanced pathology discovered only after surgery.

Important History

  • Family history of prostate cancer.
  • Previous PSA values.
  • Biopsy findings.
  • Previous urinary symptoms.
  • Comorbidities.
  • Previous treatment.

Possible Urinary Symptoms

  • Weak stream.
  • Hesitancy.
  • Frequency.
  • Urgency.
  • Hematuria.

Symptoms Suggesting Advanced Disease

  • Bone pain.
  • Back pain.
  • Hip pain.
  • Unexplained weight loss.

Clinical Importance

Bone Or Back Pain In A Patient With High-Risk Prostate Cancer Requires Assessment For Possible Metastatic Disease.


11. Physical Examination

Digital Rectal Examination

Evaluate:

  • Nodularity.
  • Induration.
  • Asymmetry.
  • Fixation.
  • Extension into adjacent structures.

Important Qualification

DRE is a clinical staging tool and cannot reliably determine all microscopic extraprostatic disease.

Final pathology remains essential for postoperative staging.


12. PSA and Related Biomarkers

PSA

PSA helps assess the probability of prostate cancer and contributes to preoperative risk prediction.

Historical Positive Predictive Values

For PSA 4–10 ng/mL:

12–32%.

For PSA greater than 10 ng/mL:

60–80%.

These values relate to cancer detection in historical populations, not directly to the probability of pT3–pT4 disease.

Factors Influencing PSA

  • Benign prostatic enlargement.
  • Prostatitis.
  • Infection.
  • Instrumentation.
  • Five-alpha-reductase inhibitors.
  • Prostate volume.

PSA Density

PSA divided by prostate volume.

Historical thresholds:

  • Greater than 0.15 ng/mL/cm³: Increased suspicion of cancer.
  • Greater than 0.35 ng/mL/cm³: Associated with a historical reported 66% risk of extraprostatic extension.

PSA Velocity

The original source uses a historical threshold of:

Greater than 0.75 ng/mL/year.

It recommends evaluating at least three measurements over approximately 18 months.

Percentage Free PSA

The historical source reports that less than 10% free PSA was associated with a cancer detection probability of approximately 56%.

PCA3

The source reports:

  • Sensitivity: 48%.
  • Specificity: 79%.

Contemporary Interpretation

These biomarkers primarily support diagnostic assessment rather than definitive pathological staging.

Neither PSA Density, PSA Velocity, Free PSA, Nor PCA3 Can Independently Establish pT3–pT4 Prostate Cancer.


13. Preoperative Imaging

Multiparametric Prostate MRI

Used to evaluate:

  • Extraprostatic extension.
  • Seminal vesicle involvement.
  • Possible adjacent structure invasion.
  • Suspicious intraprostatic lesions.

The historical source discusses 3-Tesla MRI and endorectal coils as potential methods for improving staging accuracy.

CT Abdomen and Pelvis

Historically recommended for patients with:

  • PSA greater than 20 ng/mL.
  • Gleason score 8 or higher.
  • Clinical T3–T4 disease.

Bone Scintigraphy

Used to investigate suspected skeletal metastases.

Historical Additional Investigations

  • Axial MRI.
  • PET imaging.
  • Immunoscintigraphy.

Contemporary PSMA PET/CT

PSMA PET/CT is now an important staging tool for high-risk prostate cancer and for selected patients with postoperative PSA persistence or recurrence.

Important Principle

Preoperative And Postoperative Imaging Should Be Selected According To Cancer Risk And Whether The Results Will Influence Treatment.


14. Prostate Biopsy and Final Histopathology

Preoperative Biopsy

Establishes the diagnosis and provides:

  • Histological type.
  • Gleason score.
  • ISUP Grade Group.
  • Tumour involvement.
  • Additional adverse features.

Important Limitation

Routine prostate needle biopsy may not demonstrate extraprostatic extension.

Seminal vesicle sampling may occasionally confirm suspected invasion.

Definitive Pathological Assessment

Following radical prostatectomy, examine:

  • Prostate gland.
  • Seminal vesicles.
  • Periprostatic tissues.
  • Surgical margins.
  • Regional lymph nodes when removed.

Clinical Importance

Final Surgical Histopathology Is The Basis For Determining pT3–pT4 Stage And Major Postoperative Recurrence Risks.


15. Positive Surgical Margins

Definition

A positive surgical margin (PSM) is present when cancer cells reach the inked surface of the resected specimen.

Clinical Significance

Suggests possible residual microscopic cancer at the operative site.

Important Distinction

A Positive Margin Is Not The Same As Extraprostatic Extension.

A patient may have:

  • pT2 disease with positive margins.
  • pT3 disease with negative margins.
  • pT3 disease with positive margins.

R Classification

A microscopically positive margin is generally designated:

R1.

Clinical Importance

Positive Surgical Margins Increase The Risk Of Biochemical Recurrence But Do Not Prove That Clinically Significant Cancer Remains Or That Additional Treatment Is Always Necessary.


16. Extent and Location of Positive Margins

The historical source associates more extensive margin involvement with worse outcomes.

Margin Characteristics

  • Microscopic versus extensive involvement.
  • Length of positive margin.
  • Focal versus multifocal positivity.
  • Gleason pattern at the margin.
  • Anatomical location.

Historical Adverse Locations

The source particularly emphasizes margins at the:

  • Bladder neck.
  • Vas deferens region.
  • Posterolateral prostate.

Compared with some other locations.

Historical Numerical Finding

The chapter quotes five-year progression-free figures of 65% and 40% in its comparison of gross and microscopic margin involvement, but the direction of the comparison is ambiguously presented.

The clinically relevant conclusion is that more extensive margin involvement may carry greater recurrence risk. The two percentages should not be used as precise prognostic estimates without checking the underlying study.


17. Nerve-Sparing Surgery and Margins

Clinical Objective

Preserve erectile neurovascular structures while maintaining cancer control.

Historical Source Finding

In appropriately selected patients, nerve-sparing surgery was not associated with a statistically significant increase in positive surgical margins.

Important Qualification

Patient selection is essential.

Clinical Importance

Nerve Sparing Should Be Based On The Anatomical Location And Extent Of Cancer, Not Automatically Avoided In Every Patient With Higher-Risk Disease.


18. Postoperative PSA Assessment

Expected PSA Response

Following complete removal of the prostate, PSA is expected to decline to an undetectable or extremely low level.

This usually occurs within approximately:

6–8 Weeks.

PSA Persistence

A PSA that fails to become undetectable after surgery.

A frequently used contemporary definition is:

PSA ≥0.1 ng/mL at 4–8 weeks after prostatectomy.

Biochemical Recurrence

A PSA that becomes detectable and subsequently rises after an initial postoperative response.

Conventional AUA Definition

PSA ≥0.2 ng/mL, followed by confirmatory PSA greater than 0.2 ng/mL.

Clinical Importance

The Postoperative PSA Result Is Essential For Distinguishing Patients With Adverse Pathological Features But No Detectable Cancer Activity From Patients With PSA Persistence Or Recurrence.


19. Adjuvant Versus Salvage Radiotherapy

Adjuvant Radiotherapy

Radiotherapy delivered after radical prostatectomy while postoperative PSA is undetectable, because pathological features indicate a substantial recurrence risk.

Salvage Radiotherapy

Radiotherapy delivered after PSA persistence or recurrence has been identified.

Key Distinction

Adjuvant Treatment Is Based Primarily On Pathological Risk; Salvage Treatment Is Triggered By Evidence Of Persistent Or Recurrent Disease.


20. Historical Evidence Supporting Adjuvant Radiotherapy

The original chapter summarizes three randomized trials.

SWOG 8794

Studied postoperative radiotherapy versus observation in patients with adverse pathological features.

The original source reports improved metastatic and overall survival outcomes following adjuvant radiation.

The historical chapter's quoted percentages are not clearly labeled by outcome direction. Longer-term evidence supports improvements in biochemical progression and, in this trial, overall survival.

EORTC 22911

The source describes approximately:

1,000 patients.

Historical Five-Year Progression-Free Survival

  • Adjuvant radiation: 74%.
  • Observation: 53%.

An overall survival advantage was not established in the original reported analysis.

ARO 96-02

The source describes approximately:

395 patients.

Historical Biochemical Progression-Free Survival

  • Adjuvant radiation: 72%.
  • Observation: 54%.

Clinical Importance

The Older Randomized Trials Demonstrated That Adjuvant Radiation Could Reduce Biochemical Progression In Patients With Adverse Postoperative Pathology.


21. Why Contemporary Recommendations Changed

Older randomized trials largely compared immediate adjuvant radiation with observation in which salvage radiation was not necessarily delivered early or consistently.

Later studies directly compared:

1.     Routine adjuvant radiotherapy.

2.     Close PSA monitoring with early salvage radiotherapy.

Important Modern Trials

  • RADICALS-RT.
  • RAVES.
  • GETUG-AFU 17.

ARTISTIC Meta-Analysis

Included approximately:

2,153 patients.

Five-Year Event-Free Survival

  • Adjuvant strategy: 89%.
  • Early salvage strategy: 88%.

No clear overall event-free survival advantage was demonstrated for routine adjuvant radiotherapy.

Clinical Importance

Early Salvage Radiotherapy Can Spare Many Patients Unnecessary Radiation Without Compromising Event-Free Outcomes In The Populations Studied.

Important Qualification

Very-high-risk pathological subgroups were less extensively represented, so adjuvant treatment remains a consideration in selected patients.


22. Contemporary Indications for Adjuvant Radiotherapy

For patients with undetectable postoperative PSA, most do not need immediate adjuvant radiotherapy.

Selected High-Risk Group

Current EAU guidance recommends offering adjuvant prostate-bed radiotherapy to selected patients with:

  • pN0 disease.
  • pT3 disease.
  • ISUP Grade Group 4–5.
  • With or without positive surgical margins.

Important Principle

pT3 Disease Alone Is Not An Automatic Indication For Immediate Postoperative Radiation.

Treatment decisions should account for pathology, PSA response, life expectancy, and expected treatment toxicity.


23. Early Salvage Radiotherapy

Clinical Role

A potentially curative treatment for persistent or recurrent microscopic prostate cancer after radical prostatectomy.

Typical Target

The prostate bed.

Selected patients may also require pelvic nodal radiation.

Main Clinical Principle

Salvage radiotherapy is generally more effective when given at a lower PSA concentration.

Contemporary AUA Guidance

Deliver indicated salvage radiotherapy while PSA is:

≤0.5 ng/mL.

In selected high-risk patients, treatment may be offered with a confirmed increasing PSA:

Below 0.2 ng/mL.

Clinical Importance

Do Not Delay Appropriate Salvage Radiotherapy Until PSA Becomes Markedly Elevated.


24. Imaging Before Salvage Treatment

PSMA PET/CT

May help identify:

  • Prostate-bed recurrence.
  • Pelvic lymph node metastases.
  • Distant lymph node involvement.
  • Bone metastases.

Pelvic MRI

May help identify a local recurrence.

Important Limitation

A negative PSMA PET/CT does not exclude microscopic cancer.

Clinical Importance

A Negative PSMA PET/CT Should Not Be The Sole Reason For Withholding Otherwise Indicated Early Salvage Radiotherapy.


25. Radiotherapy Technique

Historical Treatment

The original chapter emphasizes postoperative external-beam radiotherapy using approximately:

60 Gy.

Contemporary Techniques

  • Intensity-modulated radiotherapy.
  • Volumetric modulated arc therapy.
  • Image-guided radiotherapy.

Clinical Objective

Deliver an effective dose to the prostate bed while limiting injury to:

  • Bladder.
  • Rectum.
  • Urethral anastomosis.
  • Surrounding pelvic structures.

Important Qualification

Radiation dose and fractionation must be individualized and should not be copied directly from historical trials.


26. Adding ADT to Salvage Radiotherapy

Historical Source

The chapter states that randomized evidence supporting ADT with salvage radiation was not yet available.

Contemporary Position

Randomized evidence now demonstrates benefits from combining salvage radiation with ADT in appropriately selected patients.

Important Clinical Trials

  • GETUG-AFU 16.
  • RTOG 9601.
  • SPPORT.

Clinical Importance

ADT May Improve Outcomes When Combined With Salvage Radiotherapy, Especially In Patients With High-Risk Recurrence Features.


27. High-Risk Features Supporting ADT

Contemporary AUA guidance identifies important features such as:

  • PSA at salvage treatment approximately 0.7 ng/mL or greater.
  • ISUP Grade Group 4–5.
  • PSA doubling time ≤6 months.
  • Persistent postoperative PSA.
  • Seminal vesicle invasion.

Clinical Importance

High-Risk Patients Undergoing Salvage Radiotherapy Should Generally Be Offered ADT As Part Of Shared Treatment Decision-Making.


28. Duration of ADT With Salvage Radiation

Standard Minimum Duration

When ADT is selected with salvage radiotherapy:

At least 4–6 months.

Selected High-Risk Patients

May be considered for:

18–24 months.

Important Qualification

Longer treatment increases exposure to hormonal adverse effects and should be individualized.


29. ADT in pN0 Disease

Adjuvant ADT Alone

Current EAU guidance recommends:

Do not prescribe adjuvant ADT alone to pN0 patients solely because of adverse postoperative pathology.

Important Distinction

This does not prohibit ADT when it is appropriately combined with salvage radiotherapy for high-risk recurrence.

Clinical Importance

Adjuvant ADT Monotherapy And ADT Combined With Salvage Radiotherapy Are Different Treatment Strategies With Different Evidence.


30. Management of Pathological Node-Positive Disease

pN1.

Although the original chapter focuses on pN0M0 disease, it also discusses the importance of nodal metastases.

Contemporary Options Following Extended Pelvic Lymph Node Dissection

1.     Adjuvant ADT.

2.     Adjuvant ADT combined with radiotherapy.

3.     Observation in carefully selected patients.

Observation May Be Considered When

  • Two or fewer lymph nodes are involved.
  • Postoperative PSA is undetectable.
  • Other disease characteristics are favorable.

Important Qualification

Patients with higher nodal burden or persistent PSA may require more intensive treatment.

Clinical Importance

Pathological Nodal Involvement Does Not Automatically Require The Same Postoperative Treatment In Every Patient.


31. Neoadjuvant Treatment Before Prostatectomy

Historical Regimen

The source describes approximately three months of:

  • Leuprolide.
  • Flutamide.

Historical Findings

  • Reduced positive surgical margins.
  • No clear improvement in lymph node metastasis.
  • No established five-year biochemical recurrence benefit.

Contemporary Clinical Principle

Routine neoadjuvant ADT before radical prostatectomy is not established as standard care.

More intensive neoadjuvant approaches remain areas of research.


32. Postoperative Genomic Classifiers

Historical Source

The chapter suggests genomic assays may help identify which patients benefit from postoperative radiotherapy.

Contemporary Role

Selected assays may refine estimates of:

  • Biochemical recurrence.
  • Metastatic progression.
  • Prostate cancer-specific risk.

Important Qualification

Evidence supporting prognostic usefulness does not necessarily establish that every assay reliably predicts the benefit of a particular treatment.

Clinical Importance

Genomic Tests May Supplement, But Should Not Replace, PSA, Grade Group, Margin Status, And Pathological Stage When Making Postoperative Treatment Decisions.


33. Historical Salvage Radiotherapy Outcomes

The original source reports a historical series in which patients with persistent or rising PSA received salvage external-beam radiotherapy.

Four-Year Freedom From Disease

Approximately:

45%.

Four-Year Progression-Free Probability Without Adverse Features

Approximately:

77%.

Important Clinical Interpretation

Salvage treatment success depends substantially on the patient's recurrence risk.

Important Qualification

These are historical study estimates rather than universal modern treatment probabilities.

Contemporary outcomes may differ because of earlier intervention, improved imaging, and more effective combined treatment.


34. Important Prognostic Factors

Pathological Stage

  • pT3a versus pT3b.
  • pT4 involvement.

Histological Grade

  • Gleason score.
  • ISUP Grade Group.

Surgical Margins

  • Positive versus negative.
  • Extent and location of margin involvement.

Nodal Status

  • pN0 versus pN1.
  • Number of involved nodes.
  • Other nodal characteristics.

PSA Response

  • Undetectable postoperative PSA.
  • PSA persistence.
  • Biochemical recurrence.

PSA Doubling Time

A short PSA doubling time is associated with a greater risk of metastatic progression.

Clinical Importance

The Combination Of Pathological Stage, Grade Group, Margin Status, Nodal Status, And PSA Kinetics Is More Informative Than Any Single Risk Factor.


35. Complications of Postoperative Radiotherapy

Genitourinary Complications

  • Radiation cystitis.
  • Hematuria.
  • Urinary frequency.
  • Urgency.
  • Urinary incontinence.
  • Urethral or anastomotic stricture.

Gastrointestinal Complications

  • Radiation proctitis.
  • Rectal discomfort.
  • Rectal bleeding.
  • Bowel urgency.

Other Complications

  • Erectile dysfunction.
  • Lymphedema, particularly with pelvic nodal treatment.
  • Other pelvic radiation effects.

Clinical Importance

Postoperative Radiotherapy May Worsen Pre-Existing Urinary, Sexual, Or Bowel Dysfunction.


36. Complications of ADT

Vasomotor and Sexual Effects

  • Hot flushes.
  • Reduced libido.
  • Erectile dysfunction.
  • Breast tenderness or gynecomastia with some hormonal regimens.

Skeletal Effects

  • Reduced bone mineral density.
  • Osteoporosis.
  • Fractures.

Metabolic Effects

  • Increased fat mass.
  • Reduced muscle mass.
  • Insulin resistance.
  • Diabetes risk.

Psychological and Cardiovascular Effects

  • Mood changes.
  • Depression.
  • Fatigue.
  • Cardiovascular risk considerations.

Clinical Importance

The Duration And Expected Benefit Of ADT Must Be Balanced Against Its Long-Term Effects On Bone, Metabolic, Cardiovascular, Sexual, And Psychological Health.


37. Timing of Postoperative Radiotherapy and Continence Recovery

The historical source recommends allowing urinary continence to recover before radiotherapy when possible.

Rationale

  • Permit postoperative healing.
  • Improve treatment tolerance.
  • Establish baseline urinary function.

Contemporary Qualification

There is a balance between functional recovery and oncological treatment timing.

Clinical Importance

Salvage Radiotherapy Should Not Be Delayed Indefinitely For Continence Recovery When PSA Kinetics Or Pathological Risk Indicate A Need For Early Treatment.


38. Follow-Up After Radical Prostatectomy

Historical Follow-Up Schedule

First Year

Every three months.

Years 2–5

Approximately every six months.

Thereafter

Annually, depending on risk.

Contemporary EAU Framework

For clinically stable patients after curative treatment:

  • PSA approximately every six months for three years.
  • Annually thereafter.

Important Qualification

Patients with pT3–pT4 disease, persistent PSA, or active salvage treatment may require closer surveillance.


39. Follow-Up Investigations

PSA

The most important postoperative tumour marker.

Testosterone

Useful when the patient is receiving ADT or when assessing hormonal treatment response.

Imaging

Consider when:

  • PSA rises.
  • Recurrence risk is substantial.
  • Symptoms suggest progression.
  • Results would influence treatment.

Functional Follow-Up

Assess:

  • Urinary continence.
  • Lower urinary tract symptoms.
  • Erectile function.
  • Bowel symptoms.
  • Treatment adverse effects.


40. Clinical and Surgical Pearls

Pathological Staging

  • pT3a indicates extraprostatic extension.
  • pT3b indicates seminal vesicle invasion.
  • pT4 indicates invasion of adjacent structures.
  • Microscopic bladder neck invasion is pT3a.
  • Nodal status is classified separately.

Surgical Margins

  • Positive margins increase biochemical recurrence risk.
  • Margin positivity does not automatically mean clinically significant recurrence.
  • Extensive or multifocal margins may confer greater risk.
  • Margin status should be interpreted alongside Grade Group and pathological stage.

Postoperative PSA

  • PSA should become undetectable or extremely low.
  • Persistent PSA may indicate residual disease.
  • Rising PSA after initial suppression suggests recurrence.

Adjuvant Treatment

  • Historical trials established benefits of postoperative radiation in adverse pathology.
  • Modern trials support early salvage rather than routine adjuvant radiation for many patients.
  • Selected very-high-risk pN0 patients may still benefit from adjuvant radiotherapy.

Salvage Treatment

  • Early Salvage Radiotherapy Is More Effective At Lower PSA.
  • Consider treatment by PSA 0.5 ng/mL when indicated.
  • Selected high-risk patients may benefit below PSA 0.2 ng/mL.
  • Negative PSMA PET does not exclude microscopic recurrence.

ADT

  • ADT should be combined with salvage radiation in appropriately selected high-risk patients.
  • Minimum duration is usually 4–6 months when indicated.
  • Longer treatment may be appropriate for selected high-risk cases.
  • Adjuvant ADT monotherapy is not recommended routinely for pN0 disease.


41. Essential Examination Principles

1. Define Pathological T3

Extraprostatic extension or seminal vesicle invasion.

2. Distinguish T3a From T3b

T3a involves extraprostatic extension; T3b involves seminal vesicles.

3. Know the Bladder Neck Staging Detail

Microscopic bladder neck invasion is pT3a.

4. Separate Margin Status From Pathological Stage

Positive margins are reported independently.

5. Identify High-Risk Pathology

Grade Group 4–5, seminal vesicle invasion, extensive positive margins, and nodal involvement.

6. Understand PSA Persistence

Failure of PSA to become undetectable after surgery.

7. Know the Conventional BCR Definition

PSA at least 0.2 ng/mL with confirmation.

8. Distinguish Adjuvant and Salvage Radiation

Adjuvant treatment is given with undetectable PSA; salvage treatment follows evidence of residual or recurrent disease.

9. Understand the ARTISTIC Evidence

Routine adjuvant radiation did not improve five-year event-free survival compared with early salvage policy in the overall studied population.

10. Remember the Selected Adjuvant RT Group

pN0, pT3, ISUP Grade Group 4–5, with or without positive margins.

11. Treat Recurrence at a Low PSA

Salvage radiation should generally be delivered at PSA no higher than 0.5 ng/mL when indicated.

12. Recognize the Role of PSMA PET

Useful for localizing disease but cannot exclude microscopic recurrence when negative.

13. Add ADT for High-Risk Recurrence

Randomized evidence now supports combined treatment.

14. Know the Minimum ADT Duration With Salvage Radiation

Approximately 4–6 months.

15. Remember the pN1 Options

ADT, ADT plus radiation, or observation in selected limited-node disease with undetectable PSA.

16. Monitor Long-Term Functional Outcomes

Continence, erectile function, bowel symptoms, and treatment-related toxicity.


42. Historical Clinical Context and Important Qualifications

Chapter Title

The source heading refers to clinical T3–T4 disease, but the content specifically concerns pathological T3–T4 disease after radical prostatectomy.

Bladder Neck Invasion

The historical staging description includes bladder neck invasion under T4.

Contemporary staging classifies microscopic bladder neck involvement as pT3a.

PSA Screening and Stage Migration

The historical chapter discusses screening guideline changes and potential increases in advanced disease.

These are historical population observations rather than direct predictions of current stage distribution.

PSA Predictive Values

The source contains several historical PSA, PSA density, and free PSA thresholds.

These should not replace modern multivariable staging and risk assessment.

Surgical Margins

The original description of gross versus microscopic margin outcomes includes numerical ambiguity.

The appropriate clinical conclusion is that margin extent and location may influence recurrence risk.

Adjuvant Radiation

The historical chapter strongly supports immediate adjuvant radiation based on three older randomized trials.

More recent randomized trials favor an early salvage strategy for many patients with postoperative undetectable PSA.

Very-High-Risk Patients

Contemporary EAU guidance still recommends offering adjuvant prostate-bed radiation in selected pN0, pT3 patients with Grade Group 4–5.

ADT With Salvage Radiation

The source states that no level I randomized evidence was available.

This statement is outdated. Subsequent randomized trials support ADT with salvage radiation in appropriate risk groups.

Neoadjuvant Hormonal Therapy

The source describes reduced positive margin rates without demonstrated survival benefit.

Routine neoadjuvant ADT before prostatectomy remains unestablished.

Molecular Imaging

The historical source predates routine PSMA PET/CT.

PSMA PET has become important in selected postoperative staging and recurrence assessments.

Historical Radiotherapy Outcomes

Reported freedom-from-progression percentages reflect older treatment techniques, PSA thresholds, and patient selection.

They should not be used as individualized modern prognostic estimates.


43. Historical Diagnostic Codes

ICD-9

185

Malignant neoplasm of prostate.

198.1

Secondary malignant neoplasm of other urinary organs.

198.82

Secondary malignant neoplasm of genital organs.

ICD-10 Codes Listed in the Source

C61

Malignant neoplasm of prostate.

C79.11

Secondary malignant neoplasm of bladder.

C79.82

Secondary malignant neoplasm of genital organs.

Coding Qualification

These codes are preserved for historical revision.

Direct contiguous invasion of adjacent structures from a primary prostate cancer should not automatically be coded as a separate secondary metastatic malignancy. Coding must reflect the documented anatomical involvement, disease status, and applicable classification.


Final Urological Revision Summary

Pathologically advanced prostate cancer following radical prostatectomy is characterized by tumour extension beyond the prostate or invasion of adjacent structures.

Pathological Staging

  • pT3a: Extraprostatic extension, including microscopic bladder neck invasion.
  • pT3b: Seminal vesicle invasion.
  • pT4: Invasion of adjacent structures other than seminal vesicles.
  • pN0/pN1: Regional lymph node status recorded separately.

Main Adverse Prognostic Features

  • High Grade Group.
  • Advanced pathological T stage.
  • Seminal vesicle invasion.
  • Positive surgical margins.
  • Extensive margin involvement.
  • Lymph node metastases.
  • Persistently detectable postoperative PSA.
  • Short PSA doubling time.

Important Diagnostic Assessments

1.     Final prostatectomy pathology.

2.     Surgical margin assessment.

3.     Lymph node evaluation.

4.     Postoperative PSA.

5.     Serial PSA kinetics.

6.     PSMA PET/CT when indicated.

7.     Additional imaging based on recurrence risk.

Main Contemporary Postoperative Treatment Strategies

Undetectable PSA With Adverse Pathology

  • Close PSA surveillance and early salvage radiation when indicated.
  • Selected very-high-risk patients may be offered adjuvant radiotherapy.

Persistent or Recurrent PSA

  • Early salvage radiotherapy.
  • ADT when high-risk features are present.
  • Consider pelvic lymph node radiation in selected patients.

Pathological Node-Positive Disease

  • Adjuvant ADT.
  • Adjuvant ADT with radiotherapy.
  • Observation in selected patients with limited nodal involvement and undetectable PSA.

Main Treatment Complications

  • Urinary incontinence.
  • Erectile dysfunction.
  • Radiation cystitis.
  • Radiation proctitis.
  • Urethral or anastomotic stricture.
  • Lymphedema.
  • ADT-related osteoporosis.
  • Metabolic and cardiovascular complications.

Long-Term Monitoring

  • Serial PSA.
  • Testosterone when receiving ADT.
  • Evaluation of urinary and sexual function.
  • Monitoring of radiation complications.
  • Bone and metabolic health assessments.
  • Imaging when clinically indicated.

The Central Urological Objective Is To Use Final Pathological Stage, Grade Group, Margin Status, Nodal Status, And Postoperative PSA To Identify Patients At Risk Of Recurrence, Avoid Unnecessary Adjuvant Treatment, Deliver Early Salvage Radiotherapy When Indicated, Add ADT Selectively, And Preserve Long-Term Cancer Control And Quality Of Life.

Current guideline basis: The staging and management updates reflect the EAU prostate cancer guidance, the AUA/ASTRO/SUO salvage therapy guideline, and randomized evidence comparing adjuvant with early salvage radiotherapy. 

 

Image description
0 Comments